Clinical Trial Update: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring a chemotherapy-free, pCR-guided strategy using trastuzumab, pertuzumab, and T-DM1 in HER2-positive early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)
• Perjeta (pertuzumab)

Snippet

Sponsor: MedSIR | Conditions: Early Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING